{
    "clinical_study": {
        "@rank": "4795", 
        "arm_group": [
            {
                "arm_group_label": "Active Comparator: 1", 
                "arm_group_type": "Active Comparator", 
                "description": "up to 30 mg pioglitazone, tablet, orally, once daily"
            }, 
            {
                "arm_group_label": "Sham Comparator: 1", 
                "arm_group_type": "Sham Comparator", 
                "description": "up to 4 mg/day glimepiride, tablet, orally, once daily"
            }
        ], 
        "brief_summary": {
            "textblock": "Excess visceral fat is associated with chronic systemic inflammation and cardiovascular\n      complications. Pioglitazone has been reported to variably influence visceral fat volume, but\n      it its effect on metabolic activity of the visceral fat remains uncharacterized. To evaluate\n      the effect of pioglitazone on glucose metabolism of fat tissue by using\n      18F-fluorodeoxyglucose (FDG)-positron emission tomography (PET) and computed tomography (CT)\n      imaging."
        }, 
        "brief_title": "Pioglitazone Decreases Visceral Fat Metabolism", 
        "condition": "To Evaluate the Effect of Pioglitazone on Glucose Metabolism of Fat Tissue by Using FDG-PET/CT Imaging", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subjects between the ages of 35 and 85 years\n\n          -  Subjects with impaired glucose tolerance and type 2 diabetes\n\n        Exclusion Criteria:\n\n          -  Subjects with insulin treatment\n\n          -  Subjects with uncontrolled diabetes, hypertension, symptomatic coronary artery\n             disease, symptomatic cerebrovascular disease\n\n          -  Subjects taking more than three antidiabetic medications\n\n          -  Subjects taking anti-platelet, statins, antidiabetic agents, thiazolidinediones\n             within 8 weeks prior to randomization\n\n          -  Subjects with cardiac failure (New York Heart Association Class > III) or left\n             ventricular dysfunction (LVEF < 40%)\n\n          -  Subjects with systemic disorders such as active inflammatory, liver, renal,\n             hematopoietic, and malignant disease"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "58 Years", 
            "minimum_age": "35 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 24, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01819402", 
            "org_study_id": "PIO FAT"
        }, 
        "intervention": {
            "arm_group_label": [
                "Active Comparator: 1", 
                "Sham Comparator: 1"
            ], 
            "intervention_name": "Pioglitazone vs Glimepiride", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Glimepiride", 
                "Pioglitazone"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": "visceral fat metabolism; FDG-PET/CT; pioglitazone; glimepiride; adiponectin", 
        "lastchanged_date": "March 24, 2013", 
        "location": {
            "contact": {
                "email": "ntahara@med.kurume-u.ac.jp", 
                "last_name": "Nobuhiro Tahara, MD, PhD", 
                "phone": "+81-942-31-7580"
            }, 
            "facility": {
                "address": {
                    "city": "Kurume", 
                    "country": "Japan", 
                    "zip": "830-0011"
                }, 
                "name": "Kurume University"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "2", 
        "official_title": "Effects of Pioglitazone on Visceral Fat Metabolic Activity", 
        "other_outcome": {
            "measure": "All cardiovascular events and all cause death for 5 years", 
            "safety_issue": "Yes", 
            "time_frame": "Baseline and 5 years after treatment"
        }, 
        "overall_contact": {
            "email": "ntahara@med.kurume-u.ac.jp", 
            "last_name": "Nobuhiro Tahara, MD, PhD", 
            "phone": "+81-942-31-7580"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Japan: Ministry of Health, Labor and Welfare", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "April 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Effect of treatment on the nominal change in FDG uptake of fat tissue from baseline after 16 weeks of treatment as measured by FDG-PET/CT imaging.", 
            "safety_issue": "Yes", 
            "time_frame": "Baseline and 16 weeks after treatment"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01819402"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Kurume University", 
            "investigator_full_name": "Nobuhiro Tahara", 
            "investigator_title": "MD, PhD", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "Change from baseline in plasma glucose/insulin homeostatic parameters and circulating inflammatory markers", 
            "safety_issue": "Yes", 
            "time_frame": "Baseline and 16 weeks after treatment"
        }, 
        "source": "Kurume University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Kurume University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2013"
    }
}